

Quantitative Modelling of Adverse Outcome Pathway for Risk Assessment

WANG GAO (INERIS UTC)

SOUS DIRECTION DE

GHISLAINE GAYRAUD (LMAC UTC)

FRÉDÉRIC Y. BOIS (INERIS)

Overview

- I Introduction
- I.1 Toxicology in general
- I.2 Project Eu-ToxRisk21
- I.3 AOP and qAOP
- I.4 Objectives of my thesis
- II Probabilistic Model
- II.1 BN : Bayesian Networks
- II.2 DBN : Dynamic Bayesian Networks
- II.3 Model family for qAOP
- III Learning problem

IV - Conclusion

I. Introduction

I.1. Toxicology in general

- Toxicology

- Application domains: Cosmetics, Drug, etc.
- Objective: Risk assessment
- Approaches (Different types of routines)
 In vivo test: Animal experiments
 - Alternative methods
 - In vitro test (Classic) fast
 - *In vitro* test (advanced): High throughput screening very fast *In silico* test: computational modelling and simulation - we are working on this



High-throughput screening

Robotic tools

384, 1536, 3456 wells

- Fast

- Low-cost



I.2. Project Eu-ToxRisk21

"An Integrated European 'Flagship' Programme Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st century."

Organisation :

Long range 2016-2020 research program

♦41 international research teams (40 EU + 1 USA) from 13 countries

14 Work packages with sub-objectives
 WP 10 : Computational Modelling for Risk assessment

Motivation :

- Partially replace animal experimentations
- Improve the predictive methods based on high-throughput toxicity tests

15 Case studies

Liver

Kidney

Lung

Nervous system

Etc.

15 Cases are studied in the program Eu-ToxRisk21



I.3. AOP and qAOP

EU-ToxRisk21

 An Integrated European 'Flagship' Programme Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st century

***AOP** : Adverse outcome pathway – qualitative tool for mechanism description

\$ qAOP : quantitative AOP for risk assessment

Remark : Each case study corresponds to a set of AOPs.

AOP and qAOP

AOP : Adverse outcome pathway

Knowledge Exchange

- A qualitative tool for the structural representation of causal relationships (Dose-response)
 - Starting from a molecular perturbation (MIE)
 - Through key events (KE)
 - Arriving at an adverse outcome (AO)
- In this case : AO = Steatosis (fat liver)
- qAOP = quantitative AOP:
 - Probabilistic model
 - Predictive capacity : Decision Support Tool



A richer version of AOP : AOP Network



I.4. Objectives of my thesis

Objectives :

Probabilistic modelling of AOP =: qAOP

♦=> Prediction of AO

Action plan :

- Fixed structure for mini AOP
 - Modelling of the strength cause-effect
 - Prediction
- Structural learning : more ambitious



II. Probabilistic Model

II.1. BN : Bayesian Networks

- Def : BN : $(\mathcal{G}, P_{\mathcal{G}})$ with
- G : BN Structure : DAG directed acyclic graph G(V, E)
 - V : Set of vertices, nodes : variables $V = \{X_i | i \in 1: N\}$
 - *E* : Set of directed edges : causality relationships
- $P_{\mathcal{G}}$: multivariate distribution over V

• specified as set of local conditional probability distribution (CPDs) associated with G's nodes.

$$P_{\mathcal{G}}(X) = \prod_{i=1:N} P_{\mathcal{G}}(X_i | \operatorname{Par}(X_i))$$

with $X = (X_1, \dots, X_i, \dots, X_N)$ system stat vector

$$P_{\mathcal{G}}(X) = \prod_{i=1:N} P_{\mathcal{G}}(X_i | \operatorname{Par}(X_i))$$

Local conditional distributions (CPD) and the DAG completely determine the joint distribution

Example : steatosis case



<u>Problem in the context of qAOP :</u> Child node = function (Parent node(s) , time)

II. 2. DBN : Dynamic Bayesian Networks

Extension of BNs to handle temporal models

Assumptions:

- the timeline discretised into a set of *time slices* :
 - $X^{(t_0)}, \overline{X^{(t_1)}, ..., X^{(t_m)}}$, with *m* the number of observations

- Markov assumption for a dynamic system over the template variables $X : \forall i \in \mathbb{N}^+$

 $X^{(t_{i+1})} \perp X^{(t_0:(t_{i-1}))} | X^{(t_i)}$

Two types of dependency :

- Intertime-slice dependency (between time-slices)
- Intra time-slice dependency (in the same time-slice)



C child node : C_t child node at time t P parent node : P_t parent node at t

DBN : Dynamic Bayesian Networks

Markov assumption :

$$X^{(t_{i+1})} \perp X^{(t_0:(t_{i-1}))} | X^{(t_i)}$$

Compact definition of the joint probability distribution in DBN

$$P(X^{(t_0:t_m)}) = P(X^{(t_0)}) \prod_{i=1}^m P(X^{(t_i)} | X^{(t_{i-1})})$$

Example : Linear Dynamic System

Classic linear DBN

$$\mathbb{E}[C_{t_i}] = \alpha + \beta_{prev}C_{t_{i-1}} + \beta_{curr}P_{t_i}$$



Insights about qAOP

Data visualization DEMO : Real data for kidney disease case study

Dynamic 3D plot GSH-DCF-Time (online) (local)

 S_C : Stationary state (Saturation level) of child node, denote :

- $S_C = f(P_t)$: Dependence of S_C on P_t
- C_t : Child node activity at time t
- C_t converges to S_c over time



II.3. Model family for qAOP : Embryonic form

$$S_C[P_t] - \mathbb{E}[C_t] = (S_C[P_t] - C_{t-h})e^{-\nu h}$$

- *C_t* : Child node activity at time *t*, (observed)
- *P_t* : Parent node(s) activity at time *t*, I could be a vector (observed)
- $S_C[P_t]$: stationary state of child node given its parent(s) (unobserved)

Questions :

 $S_C[P_t] = ?$

 $h \in \mathbb{R}^+$: non regular observation ?

 $\nu > 0$: to ensure the convergence of C_t towards $S_C(P_t)$

$$\begin{cases} S_C[P_t] - \mathbb{E}[C_t] = (S_C[P_t] - C_{t-h})e^{-\nu h} \\ S_C[P_t] = \beta P_t + \beta_0 \\ h \in \mathbb{R}^+ \end{cases} \quad (\mathcal{M}_L)$$

Assumption : Stationary stat of Child node is a **linear function** of parent node(s)

Remark : The classic linear DBN model is a special case of (\mathcal{M}_L)

$$S_{C}[P_{t}] = \frac{\beta_{curr}}{1 - \beta_{prev}} P_{t} + \frac{\alpha}{1 - \beta_{prev}}$$

$$h = 1$$

$$e^{-\nu h} = e^{-\nu} = \beta_{prev}$$

$$\mathbb{E}[C_{t_{i}}] = \alpha + \beta_{prev} C_{t_{i-1}} + \beta_{curr} P_{t_{i}}$$

Child





III. Inference

AIGM - TOULOUSE - 14 DEC. 2017

III.1. Input – Steatosis (real)

Real public domain databases (available before my thesis)

- ToxCast
- TG-Gate

DEMO : Steatosis real data (use online DEMO link)

Problems :

The experiments are not designed for qAOP modelling.

- Very few number of data : 3 endpoints
- Discretization assumption may fail because the measurements of the system state taken at intervals that are regularly spaced with a predetermined time granularity Δt
- observations on time t = 2h 8h and 24h

Input – Steatosis (simulated)

Data simulated from pharmacokinetics models based on ODE

Three virtual experimentation conditions:

- One injection of chemical X, without dicreasing feature $\forall i \in I$, $C_X^{(t_i)} = C_X^{(0)}$
- One injection of chemical X, with decreasing feature. $\forall i \in I$, $C_X^{(t_i)} < C_X^{(t_{i-1})}$
- Four injection of chemical X, with decreasing feature : $\frac{C_X^{(0)}}{4}$ each time

online DEMO : Steatosis Generated data

Input – Kidney disease (real)

Data of kidney disease from Eu-ToxRisk21

- 5 doses
- 8 replicates
- 103 observations endpoints
 - measured on time $t_i = 1 + 15 \times (i 1)$ minutes $\forall i \in 1: 10$:



III.2. Parameters learning : linear model

$$\begin{cases} S_C[P_t] - \mathbb{E}[C_t] = (S_C[P_t] - C_{t-h})e^{-\nu h} \\ S_C[P_t] = \frac{\beta P_t}{h \in \mathbb{R}^+} + \beta_0 \\ h \in \mathbb{R}^+ \end{cases} \quad (\mathcal{M}_L) \end{cases}$$

Parameter estimation based on observations

Frequentist approach

$$\hat{\theta}_{ML} = \underset{\theta \in \Theta}{\operatorname{argmax}} L(\theta | \mathcal{D}) = \underset{\theta \in \Theta}{\operatorname{argmax}} P(\mathcal{D} | \theta)$$

Bayesian approach

$$\hat{\theta}_{MAP} = \underset{\theta \in \Theta}{\operatorname{argmax}} P(\mathcal{D} \mid \theta) \pi(\theta)$$

- Algorithm MCMC under the probabilistic programming language "stan"

III.3. Implementation: Simulated data

Parameter learning for a local conditional model :

 $P(FAS \mid LXR, t)$

Result :

Sigmoid model works significantly better with small set of data

The linear model works as well as Sigmoid with large set of data

Implementation : Kidney disease (real)



IV. Conclusion

AIGM - TOULOUSE - 14 DEC. 2017

Conclusion

Proposition of qAOP model family: Linear model, Sigmoid model

Application on Steatosis (real), steatosis (simulated), kidney disease (real).

- Steatosis (real): Not fit well, not enough data.
- Steatosis (simulated):
 - The sigmoid model fits better when only few data are available
 - The Linear model fits as well as the sigmoid model when more data are available
- Kidney disease (real):
 - Linear models can well fit the database.

Future steps:

- Test sigmoid model on Kidney disease data
- Test model performance (behaviour) on simulated data with more nodes in AOP
- QAOP network problems: hierarchical DBN.

Reference

Boyen, X. and Koller R, D., Tractable Inference for Complex Stochastic Processes, In UAI-98, 1998.

Murphy, K. P., Dynamic Bayesian Networks: Representation, Inference and Learning, PhD thesis, UC Berkeley, Computer Science Division, July 2002.

Koller R, D., Friedman, K., Probabilistic Graphical Models: Principles and Techniques - Adaptive Computation and Machine Learning, The MIT Press, 2009

Friedman, N., Murphy, K., and Russel, S., Learning the structure of dynamic probabilistic networks, In 12th UAI, 1998.

Kalman, R. E., A New Approach to Linear Filtering and Prediction Problems, Transactions of the ASME--Journal of Basic Engineering, 1960.

Thank you for your attention